

REMARKS

Claims 30-78 are active in this application. Support for these claims is found in Claims 1-29 and the specification as originally filed. The claims are directed to the elected invention, i.e., Group I drawn to nucleic acids encoded proteins and fragments thereof, including expression vectors and nucleic acid detection reagents. With respect to the method claims, Applicants request that upon finding that the elected claims are allowable, the corresponding non-elected process claims be rejoined. (MPEP § 821.04).

The rejection of the claims under 35 U.S.C. § 102(a) or 35 U.S.C. § 103(a) in light of Kannouche et al is obviated by the cancellation of those specific claims. However, as this rejection may apply to the claims presented herein, Applicants are submitting a Declaration under 37 C.F.R. § 1.132 to state that the work described in the Kannouche publication is their own work. Therefore, the Kannouche publication is not a publication by another according to 35 U.S.C. § 102(a) and withdrawal of these rejections is requested.

The specification has been amended in accordance with the Examiner's suggestion.

Formal drawings are submitted herewith to comply with the drawing requirements.

The rejections under 35 U.S.C. § 112, second paragraph, are addressed by amendment.

Lastly, the documents cited on the International Search and Preliminary Examination Reports are listed on the attached PTO-1449 Form.

Applicants submit that the present application is now ready for allowance. Early notice of such allowance is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

Tel.: (703) 413-3000
Fax: (703) 413-2220

Marked-Up Copy
Serial No: 09/555,529
Amendment Filed on: HERewith

IN THE TITLE

Page 1, line 1, please replace the title with the following substituted title:

ISOLATED POLYNUCLEOTIDES ENCODING KIN17 PROTEINS [Sequence encoding a
kin17 protein and uses thereof]

IN THE SPECIFICATION

Page 10, between lines 24 and 25, please insert the following heading:

BRIEF DESCRIPTION OF THE DRAWINGS

Page 20, please replace the paragraph bridging pages 20 and 21 as follows:

The revelation is carried out using the TSA[™] (Tyramide Signal Amplification) Direct kit (NEN kit Ref. NEL 731). After hybridization, the slides are successively washed 3 times for 10 min. in 2 X SSC, 1 X SSC and 0.5 X SSC buffer at room temperature, and then 3 times for 5 min. in 0.1 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05% Tween-20 buffer (TNT). The cells are then incubated with a blocking buffer composed of 0.1 M Tris-HCl pH 7.5, 0.15 M NaCl and 0.5% of blocking reagent for 30 min. After blocking, the immunodetection is carried out for 90 min. with a peroxidase-coupled anti-digoxigenin antibody (Boehringer Mannheim, Ref. 1207733). The antibody is used at a dilution of 1/100 in the blocking buffer of the hybridization kit (TSA[™] Direct). The incubation is followed by 3 5-min. rinses in the TNT buffer, and then the peroxidase is detected by reacting the fluorescein-coupled tyramide for 5 min. as described by the supplier (TSA[™] Direct, NEN). After 3 5-min. washes in the

TNT, the cells are stained with a solution of 10^{-3} $\mu\text{g/ml}$ of 4',6-diamidino-2-phenylindole (DAPI) for 10 min. The slides are then rinsed in the TNT buffer, before being mounted using [Vectashield] VECTASHIELD®, which is a fluorescence-protecting mounting product (Vector Laboratories, Ref. H-1000). The fluorescein is observed at 525 nm and the DAPI at 425 nm using a Carl Zeiss Axiophote 2 microscope equipped for indirect immunofluorescence and with a cooled camera, as specified above.

IN THE CLAIMS

--1-29. (Cancelled).

30-80. (New).--